<DOC>
	<DOCNO>NCT02607527</DOCNO>
	<brief_summary>Multi center evaluation Millipede IRIS treatment clinically significant mitral regurgitation subject determine appropriate mitral valve surgery .</brief_summary>
	<brief_title>Annular Reshaping Mitral Valve MR Using Millipede IRIS System</brief_title>
	<detailed_description>Multi center evaluation Millipede IRIS treatment clinically significant mitral regurgitation subject determine appropriate mitral valve surgery . This trial design accordance 2014 ACC/AHA guideline valvular heart disease , consensus statement MVARC 2015 . Subjects undergo transatrial implantation Millipede IRIS implant two approach . One ( 1 ) beat heart cardiopulmonary bypass . The second approach ( 2 ) Investigator discretion , subject qualify implant Millipede IRIS via right mini thoracotomy . The two implant technique may use clinical protocol .</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Presence symptomatic severe MR ( effective regurgitant orifice ( ERO ) ≥0.2 cm2 Secondary MR , ERO ≥0.4 cm2 Primary MR ) The New York Heart Association Functional Class II , III ambulatory IV . Left Ventricular Ejection Fraction ( LVEF ) ≥20 % ≤50 % Creatine KinaseMB ( CKMB ) obtain within prior 14 day &lt; local laboratory Upper Limit Normal ( ULN ) . Left Ventricular End Systolic Dimension ( LVESD ) ≤ 65 mm assess TTE Exclusion Criteria : Untreated clinically significant coronary artery disease require revascularization . Presence follow : Estimated pulmonary artery systolic pressure ( PASP ) &gt; 70 mmHg assess site base echocardiography right heart catheterization Hypertrophic cardiomyopathy , restrictive cardiomyopathy , constrictive pericarditis , structural heart disease cause heart failure dilate cardiomyopathy either ischemic nonischemic etiology Infiltrative cardiomyopathy ( e.g. , amyloidosis , hemochromatosis , sarcoidosis ) Hemodynamic instability require inotropic support mechanical heart assistance . Hemodynamic instability define systolic pressure &lt; 90 mmHg without afterload reduction , cardiogenic shock need inotropic support intraaortic balloon pump hemodynamic support device . Physical evidence rightsided congestive heart failure echocardiographic evidence moderate severe right ventricular dysfunction . Coronary artery bypass grafting ( CABG ) within 30 day prior subject 's consent . Percutaneous coronary intervention within 30 day prior subject 's consent . Tricuspid valve disease require surgery . Aortic valve disease require surgery TAVI . Carotid surgery within 30 day prior subject registration . Implant Cardiac Resynchronization Therapy ( CRT ) Cardiac Resynchronization Therapy cardioverterdefibrillator ( CRTD ) within last 30 day prior subject registration . Need emergent urgent surgery reason plan cardiac surgery within next 12 month . Prior mitral valve leaflet surgery currently implant prosthetic mitral valve , prior transcatheter mitral valve procedure . Status 1 heart transplant prior orthotopic heart transplantation . Chronic Kidney Disease . Chronic Steroid Therapy . Cerebrovascular accident within 30 day prior subject 's consent . Severe symptomatic carotid stenosis ( &gt; 70 % ultrasound ) .Life expectancy &lt; 12 month due noncardiac condition . Active infection require current antibiotic therapy . Pregnant planning pregnancy within next 12 month . Currently participate investigational drug another device study . Severe organic lesion mitral chord retraction , severely fibrotic immobile leaflet , severely deform subvalvular apparatus . endocarditis active endocarditis last 3 month . Heavily calcify annulus leaflet , mitral valve stenosis . Congenital malformation limit valvular tissue Patient require mitral valve replacement Previously implant prosthetic mitral valve annuloplasty ring/band . Evidence LV LA thrombus , vegetation mass Left Ventricular Ejection Fraction &lt; 20 % Left Ventricular End Diastolic Diameter &gt; 65 mm Severe tricuspid regurgitation severe RV dysfunction Condition prevent transatrial access Anatomical ineligibility investigational device Known hypersensitivity contraindication procedural post procedural medication ( e.g. , contrast solution , anticoagulation therapy ) hypersensitivity nickel titanium .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>